Panacea Biotec Tax Liability for AY 2015-16 Determined as Nil Post Rectification
Panacea Biotec's tax liability for AY 2015-16 has been determined as Nil following a rectified Assessment Order from the DCIT, New Delhi, dated April 06, 2026. This rectifies errors in the previous order that had led to a demand of ₹45.71 Crore. The company anticipates no adverse financial impact.
The resolution of a significant tax demand of ₹45.71 Crore has a material positive financial impact on the company.
The company received a rectified tax order that reduced its tax liability to Nil, which is a positive outcome.
Panacea Biotec Limited announced that the Deputy Commissioner of Income Tax (DCIT), New Delhi, has issued a rectified Assessment Order dated April 06, 2026. This follows an earlier demand order dated February 27, 2026, which had disallowed certain expenditures, resulting in a total demand of approximately ₹45.71 Crore for Assessment Year 2015-16. The company had subsequently filed a rectification application to correct apparent errors in the original order, specifically concerning the double addition of disallowances and the omission of set-off for brought-forward losses.
The rectified Assessment Order addresses these errors, and as a result, the company's tax liability for AY 2015-16 has been determined as Nil. Panacea Biotec Limited does not foresee any adverse financial, operational, or other impacts arising from this order.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under regulatory impact. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.